Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
Status:
Completed
Trial end date:
2002-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients who have
stage II or stage III prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
National Cancer Institute (NCI) Rhone-Poulenc Rorer